Comparative Genomics and Proteomics in Drug Discovery Vol 58
Coordonnateurs : Parrington John, Coward Kevin
Comparative Genomics and Proteomics in Drug Discovery gives an overview of how emerging genomic and proteomic technologies are making significant contributions to global drug discovery programs, and in particular the key role that comparative genomics and proteomics play within this strategy. Each chapter is written by respected authorities, with hands-on experience, from both academic and pharmaceutical backgrounds.
1. Comparative Genomics and Drug Discovery in Trypanosomatids 2. The Practical Implications of Comparative Kinetoplastid Genomics 3. The Relevance of Host Genes in Malaria 4. Nicotinic Acetylcholine Receptors as Drug/Chemical Targets, Contributions from Comparative Genomics, Forward and Reverse Genetics 5. Discovery of Novel Sodium Channel Inhibitors - A Gene Family-Based Approach 6. 'Omics' in Translational Medicine : Are They Lost in Translation? 7. Drug-Target Discovery In Silico : Using the Web to Identify Novel Molecular Targets for Drug Action
Date de parution : 09-2019
15.6x23.4 cm
Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).
Prix indicatif 74,82 €
Ajouter au panierDate de parution : 11-2006
Ouvrage de 182 p.
15.6x23.4 cm
Thèmes de Comparative Genomics and Proteomics in Drug Discovery :
Mots-clés :
Puff Erf Ish; kinetoplastid genomics; Auditory Sensory Gating; proteomics; MuSK; global drug discovery; TNF Polymorphism; gene family-based approach; Trypanosoma Brucei; Sleeping Sickness; nAChR Subunits; Drug Target Discovery; Insect nAChR; Body Wall Muscle; RNA Editing; Malaria Infection; Nicotinic Acetylcholine Receptors; GeneCards Database; Subtelomeric Regions; Malaria Pathogenesis; Endogenous Diseases; Species Specific Genes; Depolarising Pulses; HBB Gene; HBA2 Gene; Disease State Monitoring; SM; nAChR Subtypes; Trypanosoma Congolense